The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture:

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2020-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be done to evaluate the effect of load dose of vitamin D compared to the dose of usual clinical practice, in improving mobility and reducing disability in older people following a hip fracture.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D Levels in Frail Elderly Patients With a Hip Fracture

NCT01816711

Hip Fracture Vitamin D Deficiency

COMPLETED

Interventional Trial of Vitamin D Deficiency in the Patients of General Departments

NCT00640237

Vitamin D Deficiency

UNKNOWN PHASE3

Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice

NCT02518763

Osteoporosis

UNKNOWN PHASE3

Vitamin D Supplementation and Tibia Fracture. Does it Improve Healing Rate?

NCT03232216

Tibial Fractures Vitamin D Deficiency Fracture Healing

UNKNOWN NA

Study to Document the Phenomenon of Vitamin D Deficiency and Its Added Value in Patients with Low-energy Osteoporotic Hip Fracture, in Daily Practice in Greece.

NCT06643650

Vitamin D Deficiency Osteoporosis Bone Loss, Age-Related +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hip fractures and related disabilities are important public health issues for elderly people around the world. Attending the progressive aging of the population, an increase in the number of hip fractures is expected. In fact, some studies estimate that, globally, the incidence will exceed 6 million in 2050. In Spain, approximately 33,000 hip fracture occur annually, with an overall incidence of 517 cases per 100,000 elderly people. 90% occur in people over 64 years of age and the incidence increases exponentially beyond 80 years (\> 64: 97/100000 inhabitants-year;\> 85: 1898/100000 inhabitants-year).

Regarding the functional prognosis, those patients who survive the episode of the fracture often suffer a functional impairment. Outcomes for people who survive hip fracture are of concern, with more than one-quarter dying within a two-year period, and most of them not recovering their previous functional level. More than 10 % of survivors will be unable to return to their previous residence.

Vitamin D deficiency (serum 25 hydroxyvitamin D, 25OHD, level \< 30 ng/mL) is commonly associated with hip fracture in elderly people. Without preventive treatment, however, vitamin D deficiency following hip fracture may result in proximal muscle weakness, pain, reduced dynamic balance and performance speed.

It is not clear how much Vitamin D must be taken in order to reach the optimal level. Although the benefits of supplementing patients with at least 800 to 1000 units (U)/day Vitamin D3 may be recognized, there is little information available to guide physicians regarding the appropriate management of hip fracture patients who may be severely Vitamin D deficient, specially in acute hip fracture patients.

A randomized controlled trial, including 50 older adults (aged 75 or over) who having suffered a hip fracture and with vitamin D deficiency, will be carried out. After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group. For the intervention group, participants will receive 16.000 U Calcifediol oral daily along 5 days. For the control group will receive 16.000 U Calcifediol oral weekly along 5 weeks.

Functional status will be evaluated using Barthel Index, as well the proportion of patients reaching an optimal level of 25OHD (\> 30 ng/mL) will be determined at discharge from hospital (1 month approximately), 3, 6 and 12 months of follow up.

Secondary measures include the Timed Up and Go test, gait speed test, Short Physical Performance Battery to compare the effect of the Vitamin D supplementation strategies on functional and muscle strength scales. In addition, to measure the strength and muscle mass will be used handheld dynamometer and bioimpedance analysis respectively

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Fracture Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Calcifediol (Vitamin D) loading-dose

Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days

Group Type EXPERIMENTAL

Calcifediol (Vitamin D)

Intervention Type DRUG

After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.

For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.

For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.

Both groups:

1. Will follow the usual hip fracture rehabilitation pathway.
2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)

Calcifediol (Vitamin D) at clinical practice dose

Participants in the control group will receive 16.000 U / week for five weeks

Group Type ACTIVE_COMPARATOR

Calcifediol (Vitamin D)

Intervention Type DRUG

After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.

For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.

For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.

Both groups:

1. Will follow the usual hip fracture rehabilitation pathway.
2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcifediol (Vitamin D)

After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.

For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.

For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.

Both groups:

1. Will follow the usual hip fracture rehabilitation pathway.
2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Definitions:

* Fragility hip fracture: understood as such those that are produced by trauma of low intensity (for example, falls from the own height in standing or smaller)
* Vitamin D deficiency: 25OHD serum levels \< 30 ng / mL

Exclusion Criteria

* Presence of severe functional dependence prior to fracture of the femur (Barthel Index \< 35 points)
* Diagnosis of dementia to a moderate degree (defined on "Global Deterioration Scale" (GDS) and "Functional Assessment Staging" (FAST), GDS-FAST \> 5).
* Medical conditions that contraindicate receiving vitamin D supplementation: hypercalcemia (calcemia\> 10.5 mg / dL), hyperparathyroidism; chronic renal failure with glomerular filtration rate (GFR) \<30 mL / min, calcium lithiasis; pathologies with risk of hypercalcemia (tuberculosis, sarcoidosis ...), as well as pathologies involving intestinal malabsorption.
* Hypersensitivity to the active substance or to any of the excipients.
* Use of drugs that interact with the use of vitamin D and with the risk of causing hypercalcemia (phenytoin, phenobarbital, primidone, digoxin).
* Reduced life expectancy (\<12 months) due to the presence of advanced concomitant or end-of-life conditions.

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No